Ovarian cancer: strategies for overcoming resistance to chemotherapy.
Ovarian cancer is responsible for 4% of deaths from cancer in women. Treatment comprises a combination of surgery and chemotherapy, but patients typically experience disease relapse within 2 years of the initial treatment. Further treatment can extend survival, although relapse eventually occurs again. A better understanding of the mechanisms that underlie this drug resistance should allow treatment to be optimized, so that substantial improvements in the outlook for women with this disease can be achieved.
Agarwal
Roshan
R
Section of Medicine, Institute for Cancer Research, Sutton, Surrey SM2 5NG, UK. skaye@icr.ac.uk
Kaye
Stan B
SB
D000970:Antineoplastic Agents / Q000009:adverse effects*; D015415:Biomarkers; D003131:Combined Modality Therapy; D019008:Drug Resistance, Neoplasm / Q000502:physiology*; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000628:therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000628:therapy; D017211:Treatment Failure
D000970:Antineoplastic Agents; D015415:Biomarkers